To examine a possible role of atrial natriuretic peptide (ANP) in water and electrolyte disturbances associated with thyroid disorders, plasma ANP levels were studied in patients with hyper-and hypothyroidism.
Accumulating evidence now indicates that atrial natriuretic peptide (ANP) is a circulating hormone in man and its concentration in plasma changes in various pathologic states.
Although the precise mechanism involved in the mediation of ANP secretion in man is unknown, atrial stretch consequent to hemodynamic changes or volume expansion appears to be at least one of the most important stimuli for ANP release (Sato et al., 1986; Burnett et al., 1986; Bates et al., 1986; Raine et al., 1986) . A variety of cardiovascular manifestations are associated with altered states of thyroid function (DeGroot and Leonard, 1970; Skelton and Sonnenblick, 1986) . In addition, renal functional changes in thyroid disorders may be clinically self-evident in varied patterns of water and electrolyte derangement (Bradley et al., 1974; Katz et al., 1975) . If excessive or deficient secretion of thyroid hormone influences cardiac and renal functions, plasma ANP may be altered in patients with hyper-and hypothyroidism. The present study was undertaken to test this hypothesis by measuring plasma ANP in patients with hyper-and hypothyroidism before and after treatment. treatment with methimazole or propylthiouracil, plasma ANP decreased to the normal range in 4 patients. The differences were greater than day-to-day variations in plasma ANP in all patients. Concomitantly, cardiothoracic ratios of the two patients who had cardiomegaly before therapy were reduced to 50% and 48%, respectively, and the normal sinus rhythm was restored in one patient who had had atrial fibrillation. However, the plasma ANP concentration increased in one patient who had persistent atrial fibrillation after the treatment, which may be due to decreased cardiac function judged by a decrease in the ejection fraction. The mean plasma ANP concentration in 21 untreated patients with hyperthy- 
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Discussion
The present study demonstrates that plasma ANP is increased in some patients with hyperthyroidism.
In rats, the administration of thyroid hormone has been shown to increase plasma ANP (Kohno et al., 1986a; Ladenson et al., 1986) . Gardner et al.(1986) demonstrated that increasing doses of T3 were accompanied by both increased ANP release and increased RNA transcripts of ANP in an in vitro rat neonatal cardiocyte system. In view of these patients with hyperthyroidism may be due to a direct effect of thyroid hormone on cardiomyocytes. However, hyperthyroidism is associated with various hemodynamic changes including increased cardiac output, stroke volume, heart rate; diminished peripheral vascular resistance; widened pulse pressure; and increased circulating blood volume (DeGroot and Leonard, 1970; Skelton and Sonnenblick, 1986) . Four of the 5 hyperthyroid patients whose pretreatment plasma ANP was increased had atrial fibrillation or cardiomegaly.
Plasma ANP is often increased in patients with lone atrial 1987) and in those with heart disease who have no signs or symptoms of congestive heart failure (Nakaoka et al., 1985) . The observed changes in plasma ANP in hyperthyroid patients, therefore, may be ascribed to changes in cardiovascular function, or water and electrolyte metabolism associated with this disorder rather than a direct effect of thyroid hormone on cardiomyocytes. Recently, Kohno et al. (1986b) reported increased plasma ANP in 5 of 6 hyperthyroid patients.
Whether their patients had changes in cardiac or renal function is unknown. Of note in this regard is that increased heart rate per se may not be responsible for high plasma ANP in hyperthyroid patients, since no significant correlation was found between plasma ANP and heart rate.
Replacement of thyroid hormone increased plasma ANP in most hypothyroid patients, although their pretreatment plasma ANP was within the normal range. The results generally agree with the recent report by Zimmerman et al.(1987) with an exception that they found significantly lower plasma ANP in untreated hypothyroid patients than in normal subjects. The difference between their study and ours may possibly be due to the age of the patient, since hypothyroid patients in the present study were older, and plasma ANP is shown to increase with age (Ohashi et al., 1987) . However, this seems unlikely because no clear difference in plasma ANP was found among healthy subjects in the 4th, 5th and 6th decades (Nakaoka et al., 1987) . Rather, the difference may be due to the small number of controls used in their study. In the present study, pericardial effusion was demonstrated in 4 of the 6 hypothyroid patients who showed an increase in plasma ANP after the replacement of thyroid hormone. If atrial stretch consequent to increased atrial pressure is the main factor in stimulating ANP release from cardiomyocytes, pericardial effusion may decrease ANP secretion by inhibiting atrial stretch. Further, the decreased plasma volume associated with hypothyroidism (Gibson and Harris, 1939 ) may attenuate ANP secretion, since volume expansion following saline infusion in man increases plasma ANP (Yamaji et al., 1985; Sugawara et al., 1986) . Thus, lower plasma ANP in untreated hypothyroid patients may be explained again by hemodynamic changes resulting from thyroid hormone deficiency. Whether decreased plasma ANP may be linked to generalized accumulation of water and sodium in hypothyroidism (Aikawa, 1956) remains unclear at present.
In conclusion, the present study shows that plasma ANP is increased in some patients with hyperthyroidism and that replacement of thyroid hormone increases plasma ANP in most hypothyroid patients. These abnormalities in ANP dynamics in thyroid disorders may probably be caused by the concomitant hemodynamic changes. Whether the increased or decreased plasma ANP observed in patients with thyroid disorders is really of clinical importance in volume homeostasis should be clarified by future studies.
